Acute Coronary Syndrome - Drug Pipeline Landscape, 2023

Acute Coronary Syndrome - Drug Pipeline Landscape, 2023

Acute coronary syndrome is a term for a group of conditions that suddenly stop or severely reduce blood from flowing to the heart muscle. When blood cannot flow to the heart muscle, the heart muscle can become damaged. Acute coronary syndrome causes no cell death, the reduced blood flow changes how the heart works and is a sign of a high risk of heart attack.

Acute coronary syndrome usually results from the buildup of fatty deposits (plaques) in and on the walls of coronary arteries, the blood vessels delivering oxygen and nutrients to heart muscles. Plaque can tear suddenly, and a blood clot forms around it, severely narrowing or blocking the artery.

Signs and symptoms of acute coronary syndrome includes chest pain (angina) or discomfort, shortness of breath, sudden, heavy sweating, Feeling restless or apprehensive, fast, or irregular heartbeat.

Doctors most often diagnose acute coronary syndrome by using tests like electrocardiogram (ECG), A troponin blood test can show if the cells in the heart have been damaged, echocardiogram, coronary angiography, exercise stress test, nuclear stress test, stress echocardiography.

The most common investigative treatments include aspirin, beta blockers, statins, blood thinners, clot dissolving drugs, angiotensin converting enzyme (ACE) inhibitors, or nitroglycerin. Surgeries like angioplasty, bypass surgery to route the blood around the artery that is blocked, may improve outcomes.

Report Highlights

Global Insight Service’s, Acute Coronary Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Acute Coronary Syndrome pipeline drugs. This report covers detailed insights on Acute Coronary Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acute Coronary Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.